SLStephen Leong

Stephen Leong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen Leong has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors

    by Stephen Leong, Rebecca A. Moss, Daniel W. Bowles, Joseph A. Ware, Jing Zhou, Jill M. Spoerke, Mark R. Lackner, Geetha Shankar, Jennifer L. Schutzman, Ruud van der Noll, et al.

    Background: Epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K) are involved in the proliferation and survival of many cancer types. Enhanced antitumor activity may be achieved through combined inhibition of these pathways. We report results for pictilisib (GDC-0941, a class I pan-PI3K inhibitor) plus erlotinib (an EGFR tyrosine kinase inhibitor) in patients with advanced solid tumors.Materials and Methods: A 3 + 3 dose-escalation study was carried out at a starting daily dose of 60 mg pictilisib on days 1–21 of a 28-day cycle and 150 mg erlotinib from day 2 of cycle 1. The primary objectives of the study were to assess safety and tolerability, identify dose-limiting toxicities (DLTs), estimate the maximum tolerated dose, and identify the recommended phase II dose (RP2D). Evaluation of a dose-expansion cohort at the RP2D was performed.Results: Fifty-seven patients were treated in the study. All patients experienced at least one adverse event (AE). Grade ≥3 AEs, serious AEs, and deaths were reported in 38 (66.7%), 19 (33.3%), and 4 (7.0%) patients, respectively. DLTs occurred in nine patients across eight cohorts and the RP2D was determined to be 340 mg pictilisib on a “5 days on, 2 days off” schedule plus 100 mg erlotinib. Two patients (3.5%) experienced partial response and 19 (33.3%) had stable disease.Conclusion: Combining pictilisib with erlotinib in patients with advanced solid tumors is feasible; however, antitumor activity is limited. Additional studies may identify patients likely to benefit from combined inhibition of EGFR and PI3K pathways.


  • Prognostic factors for 90-day mortality in patients with solid malignancies treated on Phase 1 trials sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute.

    by Kit Man Wong, Larry Rubinstein, Matthew Rinker, Gary Lee Smith, Elad Sharon, S. Gail Eckhardt, Wells A. Messersmith, Stephen Leong, Pamela Jo Harris, Dexiang Gao

    2533 Background: The appropriate selection of cancer patients with reasonable life expectancy is critical in Phase 1 trials. The ability to predict patient outcomes prior to enrollment, particularly their 90-day mortality (90DM), would improve selection, avoid harm in those unlikely to benefit, and maximize the meaningful data obtained. There is currently no standard prognostication strategy. We analyzed the prognostic factors of patients on Phase 1 trials sponsored by CTEP. Methods: 5,477 patients with solid tumors enrolled in CTEP Phase 1 trials from 2000 to 2015 were included. Patient, disease and lab characteristics within 30 days prior to first dose, study treatments and outcomes were extracted from a prospective database. Adjusted hazard ratios (aHR) for 90DM were analyzed by multivariate Cox regression. Results: The study population had a median age of 58 (18-90) years and 49% males. Most common tumor types were: 35% gastrointestinal, 11% breast, 10% genitourinary (GU); 94% of patients had ECOG 0-1. Most subjects received combination therapy (63%). The majority of trials tested a targeted agent (76%). 90DM was 16%; median duration on therapy (DoT) was 56 (0-1,358) days; response rate was 9%. 90DM was independently associated with worse ECOG (2 vs 0: aHR 3.8, 95% CI 2.5-5.7), high ALP ( > 2.5xULN vs < ULN: aHR 2.2, 95% CI 1.5-3.1), high LDH ( > 2.5xULN vs < ULN: aHR 2.3, 95% CI 1.7-3.1), low albumin ( < 3.0 vs > 3.5 g/dL: aHR 2.7, 95% CI 1.9-3.7), high bilirubin ( ≥ 1.3 vs < 1.3 mg/dL: aHR 1.6, 95% CI 1.2-2.2), and high white blood cells ( > 11 vs ≤ 11 x109/L: aHR 1.7, 95% CI 1.3-2.2). Those on combination regimens were more likely to live in the first 90 days (vs monotherapy: aHR 0.75, 95% CI 0.59-0.95). Therapy type (cytotoxic, targeted, immunotherapy) and tumor site were not determinants of 90DM. Similar variables predicted DoT; additional factors associated with longer DoT were GU cancers and regimens containing non-cytotoxic agents. Conclusions: This is the largest prognostic analysis of 90DM in Phase 1 trial patients. ECOG status, specific labs, and number of agents appear to be important factors. A prognostic tree algorithm will be presented.

  • Incidence of colorectal cancer among young adults in the state of Colorado.

    by Christopher Hanyoung Lieu, David Sheneman, Jack L Finch, Sarah Lindsey Davis, Stephen Leong, Colin D. Weekes, William T. Purcell, Karyn A. Goodman, Wells A. Messersmith, S. Gail Eckhardt

    3585 Background: Colorectal cancer (CRC) incidence has decreased overall, both nationally and across Colorado, since 1990. Since National Comprehensive Cancer Network (NCCN) guidelines recommend screening beginning at age 50 for individuals with average risk, little is known about the CRC incidence in individuals under age 50. However, from 1992 to 2011 there has been a continuous increase in the rate of CRC in patients under 50, which has not been evaluated by geographic region. We examined CRC incidence, focusing on age, in order to better understand CRC in the under-50 population in Colorado. Methods: We analyzed 39,575 CRC cases from the Colorado Central Cancer Registry, examining effects of age, gender, stage at diagnosis, disease location, first treatment received, and length of disease. We calculated the annual percentage change over the 23-year study period (1990 – 2013) to analyze changes in age-adjusted incident rates. Results: The age-adjusted incidence of CRC was lower in individuals under 50, ranging from 4.3 to 6.8 per 100,000 person-years compared to individuals over 50, where incidence ranged from 104.7 to 178.2 per 100,000. However, increasing age-adjusted incidence rates averaging 0.8% per year (p < 0.05) were observed in the under-50 population, while age-adjusted rates fell on average 2.5% per year (p < 0.05) in the over-50 population. Age-adjusted incidence rose in males under 50 by 1.0% per year (p < 0.05) and increased 0.8% per year in females. The increase in incidence appeared to be driven mostly by an increase in stage IV CRC in the under-50 population with an increase of 2.4% per year from 2003 through 2013 (p < 0.05) compared to an increase in early-stage CRC of 0.8% per year. Conclusions: The absolute incidence of CRC continues to fall in the state of Colorado in individuals over age 50. However, incidence is rising in individuals under age 50, particularly among males, and the increase in incidence appears to be driven by an increase in late-stage diagnosis. Additional research into CRC in individuals under age 50 is necessary to better characterize this rise in incidence and possible causative mechanisms.

  • Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers

    by Elizabeth R. Kessler, S. Gail Eckhardt, Todd M. Pitts, Erica L. Bradshaw-Pierce, Cindy L. O’bYrant, Wells A. Messersmith, Sujatha Nallapreddy, Colin Weekes, Jennifer Spratlin, Christopher H. Lieu, et al.

    Summary Background Vandetanib is a multitargeted tyrosine kinase inhibitor that affects vascular endothelial growth factor receptor (VEGF), epidermal growth factor (EGF), and rearranged during transfection (RET) mediated receptors which are important for growth and invasion of biliary and pancreatic cancers. This phase I study evaluated the safety profile of vandetanib in combination with standard doses of gemcitabine and capecitabine in order to determine the maximum tolerated dose (MTD). Methods In this single center phase I trial, patients received gemcitabine intravenously (IV) at 1000 mg/m2 days 1, 8, 15 in a 28 day cycle, capecitabine orally at 850 mg/m2 twice daily on days 1–21, and escalating doses of vandetanib (200 or 300 mg orally daily). Once the MTD was defined, an expansion cohort of patients with advanced biliary cancers and locally advanced or metastatic pancreatic cancer was enrolled. Blood samples were also collected at predetermined time points for biomarker analysis. Results Twenty-three patients were enrolled: 9 in the dose escalation and 14 in the dose expansion cohort. One dose limiting toxicity (DLT), of grade 4 neutropenia, occurred in the 200 mg vandetanib cohort. The most common adverse effects were diarrhea (39 %), nausea and vomiting (34 %), and rash (33 %). There were 3 partial responses and stable disease of >2 months (range 2–45, median 5) was observed in 15/23 patients. There was no association between changes in biomarker analytes and disease response. Conclusion The combination of gemcitabine, capecitabine and vandetanib is well tolerated at the recommended phase II dose of gemcitabine 1000 mg/m2 weekly for three consecutive weeks, capecitabine 850 mg/m2 BID days 1–21, and vandetanib 300 mg daily, every 28 days. This combination demonstrated promising activity in pancreaticobiliary cancers and further evaluation is warranted in these diseases. NCT00551096.


  • Open Access

    Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models

    by Sara A. Flanigan, Todd M. Pitts, Timothy P. Newton, Gillian N. Kulikowski, Aik Choon Tan, Martine C. McManus, Anna Spreafico, Maria I. Kachaeva, Heather M. Selby, John J. Tentler, et al.

    Purpose: Results from clinical trials involving resistance to molecularly targeted therapies have revealed the importance of rational single-agent and combination treatment strategies. In this study, we tested the efficacy of a type 1 insulin-like growth factor receptor (IGF1R)/insulin receptor (IR) tyrosine kinase inhibitor, OSI-906, in combination with a mitogen–activated protein (MAP)–ERK kinase (MEK) 1/2 inhibitor based on evidence that the MAP kinase pathway was upregulated in colorectal cancer cell lines that were resistant to OSI-906. Experimental Design: The antiproliferative effects of OSI-906 and the MEK 1/2 inhibitor U0126 were analyzed both as single agents and in combination in 13 colorectal cancer cell lines in vitro. Apoptosis, downstream effector proteins, and cell cycle were also assessed. In addition, the efficacy of OSI-906 combined with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) was evaluated in vivo using human colorectal cancer xenograft models. Results: The combination of OSI-906 and U0126 resulted in synergistic effects in 11 of 13 colorectal cancer cell lines tested. This synergy was variably associated with apoptosis or cell-cycle arrest in addition to molecular effects on prosurvival pathways. The synergy was also reflected in the in vivo xenograft studies following treatment with the combination of OSI-906 and selumetinib. Conclusions: Results from this study demonstrate synergistic antiproliferative effects in response to the combination of OSI-906 with an MEK 1/2 inhibitor in colorectal cancer cell line models both in vitro and in vivo, which supports the rational combination of OSI-906 with an MEK inhibitor in patients with colorectal cancer. Clin Cancer Res; 19(22); 6219–29. ©2013 AACR.


  • A moving target: challenges in treating BRAF-mutant colorectal cancer

    by Aaron J Scott, Stephen Leong, Wells A Messersmith, Christopher H Lieu

  • A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors

    by S. Leong, S. G. Eckhardt, E. Chan, W. A. Messersmith, J. Spratlin, D. R. Camidge, S. Diab, R. Khosravan, X. Lin, E. Chow Maneval, et al.

    Purpose This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6). Methods Patients with advanced solid malignancies received mFOLFOX6 in 2-week cycles with escalating sunitinib doses (25, 37.5, and 50 mg/day) on three schedules: 2 weeks on, 2 weeks off (2/2); 4 weeks on, 2 weeks off (4/2); or continuous daily dosing (CDD). Patients received up to 8 treatment cycles (Schedule 2/2 and CDD schedule) or 6 cycles (Schedule 4/2). An expansion cohort enrolled patients with metastatic colorectal cancer at the Schedule 2/2 MTD. Results Overall, 53 patients were enrolled, with 43 evaluable for dose-limiting toxicity (DLT). On Schedule 2/2 (n = 18), DLTs occurred in three patients at 50 mg/day (grade 4 neutropenia [n = 1]; grades 3 and 4 thrombocytopenia [n = 2]) and two patients achieved partial responses (PRs). On Schedule 4/2 (n = 13), 37.5 mg/day exceeded the MTD with two DLTs (febrile neutropenia and grade 4 hypokalemia, respectively). On the CDD schedule (n = 12), the MTD was 25 mg/day; one DLT (grade 3 stomatitis) was reported and two patients achieved PRs. The most common adverse events were neutropenia, fatigue, and thrombocytopenia. No clinically significant drug–drug interactions were apparent between sunitinib, its metabolite SU12662, and mFOLFOX6. Conclusions Sunitinib combined with mFOLFOX6 had acceptable tolerability. The MTDs were sunitinib 50 mg/day on Schedule 2/2 and 25 mg/day on the CDD schedule. A MTD for Schedule 4/2 was not established.


  • Management Strategies for Patients with KRAS Mutations

    by Stephen Leong, S. Gail Eckhardt, Wells A. Messersmith

  • Novel Agents in the Treatment of Metastatic Colorectal Cancer

    by Stephen Leong, Wells A. Messersmith, Aik Choon Tan, S. Gail Eckhardt

    Colorectal cancer (CRC) is one of the leading causes of cancer death in the United States. Research has led to an explosion of knowledge into the molecular basis of CRC in the past decades. Numerous receptors and intracellular proteins have been identified and implicated in the growth and progression of metastatic CRC, thus creating novel targets for drug development. Many agents are under development and have begun to enter early and even later-stage clinical trials. Results of these agents have demonstrated some encouraging activity but in a small number of patients. Research into predictive biomarkers aims to select the patients who may benefit from these novel agents. This review will address several of these promising new agents, their potential relevance to CRC, results from early clinical studies, and their incorporation into future and ongoing CRC clinical trials. Clearly, there is an urgent need for new agents in this disease, but as we learned from the experience with epidermal growth factor receptor-targeted antibodies, patient selection will be increasingly be required for individualized therapy to become a reality in CRC.


  • Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

    by Stephen Leong, Roger B. Cohen, Daniel L. Gustafson, Corey J. Langer, D. Ross Camidge, Kristin Padavic, Lia Gore, Margaret Smith, Laura Q. Chow, Margaret von Mehren, et al.

    Purpose: A phase I study assessed the safety, tolerability, pharmacokinetics, and preliminary antitumor effect of mapatumumab, a fully-human agonist monoclonal antibody to the tumor necrosis factor–related apoptosis-inducing ligand receptor 1 (TRAIL-R1, DR4), in combination with paclitaxel and carboplatin. Patients and Methods: Patients with advanced solid malignancies received 3, 10, or 20 mg/kg of mapatumumab with standard doses of paclitaxel and carboplatin every 21 days for up to six cycles in the absence of disease progression. Additional cycles of paclitaxel and/or mapatumumab were permissible in selected cases. Results: Twenty-seven patients (21 males), with a median age of 54 years, received mapatumumab in the following three cohorts: 3 mg/kg (n = 4), 10 mg/kg (n = 11), and 20 mg/kg (n = 12). The median number of cycles was four. Dose-limiting toxicities (DLTs) were grade 3 hypersensitivity reaction (n = 1) and neutropenic fever (n = 1), both at 10 mg/kg. Non-DLT treatment-related adverse events occurring in more than 10% of administered doses included alopecia, neutropenia, fatigue, nausea, anemia, thrombocytopenia, anorexia, and neuropathy. Paclitaxel and carboplatin exposures were similar in the presence or absence of mapatumumab. Plasma mapatumumab concentrations seemed similar to data from previous phase I monotherapy studies. Five patients (19%) achieved a confirmed radiologic partial response (including one pathologic complete response), and 12 patients (44%) had stable disease as their best response. Conclusion: Mapatumumab is well-tolerated up to 20 mg/kg in combination with paclitaxel and carboplatin. There are no apparent pharmacokinetic interactions among the drugs. Preliminary anticancer activity demonstrated clinical benefit for the majority of these patients.